1/9
08:02 am
TRVI
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
Trevi Therapeutics (NASDAQ:TRVI) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
12/19
09:53 am
TRVI
Rating for TRVI
Medium
Report
Rating for TRVI